Skip to main content
CHEMCLIN DIAGNOSTICS CO., LTD. logo

CHEMCLIN DIAGNOSTICS CO., LTD. — Investor Relations & Filings

Ticker · 688468 ISIN · CNE100005311 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2021-04-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688468

About CHEMCLIN DIAGNOSTICS CO., LTD.

https://www.chemclin.com/

CHEMCLIN DIAGNOSTICS CO., LTD. specializes in the research, development, and manufacturing of in vitro diagnostic systems and reagents. The company is primarily recognized for its proprietary Light-initiated Chemiluminescent Assay (LiCA) technology, a homogeneous chemiluminescence platform that eliminates the need for washing steps, thereby enhancing testing efficiency and precision. Its product portfolio includes fully automated immunoassay analyzers and a comprehensive range of diagnostic kits covering infectious diseases, cardiac markers, thyroid function, tumor markers, and reproductive health. By integrating advanced biotechnology with automated instrumentation, the company provides clinical laboratories and medical institutions with high-sensitivity diagnostic solutions designed to improve patient care and laboratory workflow.

Recent filings

Filing Released Lang Actions
控股股东关于科美诊断技术股份有限公司股票交易异常波动询证函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from a controlling shareholder to an inquiry about abnormal stock trading fluctuations. It explicitly states that no major corporate actions such as mergers, restructuring, or share issuance are planned. The document is very short (300 characters) and serves as a regulatory response rather than a financial report or announcement of a meeting or vote. It does not contain financial data, management discussion, or detailed disclosures. This type of document fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2021-04-19 Chinese
实际控制人关于科美诊断技术股份有限公司股票交易异常波动询证函的回函
Regulatory Filings Classification · 95% confidence The document is a response letter from the actual controller of the company regarding an inquiry about abnormal stock trading fluctuations. It explicitly states that no major events such as mergers, restructuring, or share issuance are underway. The document is very short (254 characters) and serves as a formal reply to an inquiry, not a financial report or announcement of a report. It does not contain financial data or detailed disclosures but is a regulatory communication related to stock trading activity. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2021-04-19 Chinese
科美诊断公司章程
Regulatory Filings
2021-04-07 Chinese
科美诊断首次公开发行股票科创板上市公告书
Regulatory Filings
2021-04-07 Chinese
科美诊断首次公开发行股票并在科创板上市发行结果公告
Capital/Financing Update Classification · 95% confidence The document is titled as an announcement of the results of the initial public offering (IPO) and listing on the Sci-Tech Innovation Board (科创板) for 科美诊断技术股份有限公司. It details the issuance price, number of shares issued, strategic placement, online and offline subscription results, lottery results for offline placement, underwriting details, and contact information for the sponsor and underwriter. The document is a formal announcement of the issuance and allocation results of new shares in an IPO, including subscription and allotment details, but it does not contain financial statements or comprehensive financial performance data. It is not an annual report, earnings release, or management report. It is not a proxy statement or voting results announcement. It is not a regulatory filing in the sense of compliance or certification. It is a capital market transaction update specifically about the issuance and allocation of new shares in an IPO. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance results, not just a brief notice or report publication announcement.
2021-04-01 Chinese
科美诊断首次公开发行股票并在科创板上市招股说明书
Capital/Financing Update Classification · 95% confidence The document is titled as a 招股说明书, which translates to a "Prospectus" or "Offering Document" for the company's initial public offering (IPO) and listing on the Sci-Tech Innovation Board (科创板) of the Shanghai Stock Exchange. It contains detailed information about the company's business, risks, financial data, share issuance details, governance, and other disclosures typical of an IPO prospectus. It is not an annual report, earnings release, or any other type of periodic financial report. It is a comprehensive document used to inform investors about the IPO and the company. This type of document corresponds to a Capital/Financing Update (CAP) as it relates to the company's fundraising and capital structure changes through the initial public offering.
2021-04-01 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.